Skip to main content

Table 2 Total expression levels of Biomarkers (N = 70)

From: RRM1 and ERCC1 as biomarkers in patients with locally advanced and metastatic malignant pleural mesothelioma treated with continuous infusion of low-dose gemcitabine plus cisplatin

ERCC1

 Mean (± SD)

286, 178.3 (± 219, 019.8)

 Low expression % (n)

48.9 (23)

 High expression % (n)

51.1 (24)

hENT-1

 Mean (± SD)

104, 647.1 (± 65, 773.4)

 Low expression % (n)

50 (25)

 High expression % (n)

50(25)

RRM1

 Mean (± SD)

4, 536.5 (± 5, 521.3)

 Low expression % (n)

46.4 (13)

 High expression % (n)

53.6 (15)

RRM2

 Mean (± SD)

2458.7 (± 4, 983.4)

 Low expression % (n)

48.4 (15)

 High expression % (n)

51.6 (16)

  1. Note: the total of patients varies across the different biomarkers due to the lack of tissue
  2. SD Standard deviation, ERCC1 Excision repair cross complementation-1, hENT-1 Human equilibrative nucleoside transporter-1, RRM1 Ribonucleotide Reductase M1, RRM2 Ribonucleotide Reductase M2